Stoke Therapeutics (STOK): RTW Investments, LP added to its stake +423K shares
RTW Investments, LP added to its stake in Stoke Therapeutics, per its Q4 2025 13F.
- 5.55M
- Shares reported · +423K vs prior quarter
- 1.8%
- Disclosed portfolio weight
- $176M
- Reported value
- Holdings as of
- Dec 31, 2025
- Filed
- Feb 17, 2026
What stands out in this filing
- 5,123,525 shares in Q3 2025, 5,546,856 now (+8.3% in share count).
- Reported at $176M, 1.76% of the portfolio value in this 13F filing.
- No other tracked manager reported the same kind of change for Q4 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 11, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)
- Jan 21, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
- Feb 13, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 13, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) approved a discretionary bonus of $697,125 for Ian F. Smith, the Company’s Chief Executive Officer (the “Bonus”).”
What came next
- Mar 23, 2026Company filing · Form 8-K · Auditor changeChanged its auditor“On March 23, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Stoke Therapeutics, Inc. (the “Company”) dismissed KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm.”
- Apr 3, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On April 3, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (“Stoke” or the “Company”), increased the size of the Board to ten (10) directors and, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed G. Clare Kahn, Ph.D. to serve on the Board as a Class I director, effective immediately, to fill the vacancy created by the increase in Board…”
- May 7, 2026Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Stoke Therapeutics
For Stoke Therapeutics, OQRO holds 6 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its STOK page.
How this filing works
Explore the data
Common questions
What does this filing report about Stoke Therapeutics (STOK) stock?
RTW Investments, LP added to its stake in Stoke Therapeutics, per its Q4 2025 13F. Now 5.55M shares, $176M reported value, 1.8% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2025. Filed: Feb 17, 2026.
What stands out in this filing?
5,123,525 shares in Q3 2025, 5,546,856 now (+8.3% in share count). Reported at $176M, 1.76% of the portfolio value in this 13F filing. No other tracked manager reported the same kind of change for Q4 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Stoke Therapeutics recently?
For Stoke Therapeutics, OQRO holds 6 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the STOK page.
Does this mean STOK stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Stoke Therapeutics
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 13, 2026
- SEC Form 4Nov 4, 2026
- SEC Form 4Nov 4, 2026
- SEC Form 144Oct 21, 2026
- SEC Form 144Oct 2, 2026
Everything OQRO holds on this company is on its STOK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
